NextCure (NXTC) FCF Margin (2019 - 2020)
NextCure (NXTC) posted quarterly FCF Margin of 48.04% for Q1 2020, up 47923.0% year-over-year from N/an in Q2 2019, and up 92.75% quarter-over-quarter from 662.79% in Q4 2019.
NextCure (NXTC) FCF Margin (2019 - 2020) Analysis & Trends
NextCure's FCF Margin history runs 2 years deep, the most recent figure standing at 48.04% for Q1 2020.
- In Q1 2020, FCF Margin rose 47923.0% year-over-year to 48.04%; the TTM figure through Dec 2020 stood at 201.37% (up 41300.0% YoY), while the FY2020 annual figure was 201.37%, up 41300.0% from the prior year.
- FCF Margin for Q1 2020 stood at 48.04%, up from 662.79% in the prior quarter.
- The five-year high for FCF Margin was 48.04% in Q1 2020, with the low at 756.42% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -48.04% |
| Dec 31, 2019 | -662.79% |
| Sep 30, 2019 | -501.90% |
| Jun 30, 2019 | -756.42% |
| Mar 31, 2019 | -527.27% |